Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday

Annovis Bio (NYSE:ANVS) is anticipated to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Annovis Bio (NYSE:ANVS) last released its earnings results on Friday, March 21st. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). During the same period in the previous year, the firm posted ($0.43) EPS. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Stock Down 1.0 %

Shares of Annovis Bio stock opened at $1.49 on Wednesday. Annovis Bio has a 52-week low of $1.43 and a 52-week high of $20.00. The company has a market capitalization of $21.14 million, a P/E ratio of -0.33 and a beta of 1.65. The company has a 50 day moving average of $2.54 and a 200 day moving average of $5.41.

Analysts Set New Price Targets

Separately, D. Boral Capital reaffirmed a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $37.00.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.